Zogenix Announces Conference Call And Webcast To Present Fourth Quarter And Full Year 2013 Financial Results

SAN DIEGO, Feb. 27, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced it will release financial results for the fourth quarter and full year ended December 31, 2013, after the market closes on Wednesday, March 5, 2014, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.

To access the live webcast please visit the Company's Investor Relations website at ir.zogenix.com, and to participate, please dial 877-474-9506 (U.S.) or 857-244-7559 (International); participant passcode: 23384178.

The conference call will be hosted by Chief Executive Officer Roger L. Hawley, President Stephen J. Farr, Ph.D., and Executive Vice President and Chief Financial Officer Ann Rhoads.

A replay of the conference call will be available beginning March 5, 2014 at 8:30 p.m. ET (5:30 p.m. PT) until March 12, 2014, by dialing 888-286-8010 (U.S.) or 617-801-6888 (International); passcode: 95697181. A replay of the webcast will also be accessible on the Investor Relations website for one month, through April 5, 2014.

About Zogenix

Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company committed to developing and commercializing therapies that address specific clinical needs for people living with pain-related conditions and central nervous system disorders who need innovative treatment alternatives to help them return to normal daily functioning. The Company has commercialized two products using technology to enhance the patient experience and has a development pipeline that includes a once-monthly subcutaneous injection for schizophrenia. More information about Zogenix is available at www.zogenix.com

FPR
CONTACT: Investors         Zack Kubow | The Ruth Group         646.536.7020 | zkubow@theruthgroup.com                  Media         Aaron Estrada | The Ruth Group         646-536-7028 | aestrada@theruthgroup.com

If you liked this article you might like

Biotech Premarket Movers: ChemoCentryx, Jazz, Ionis, Zogenix

These 5 Stocks Under $10 Could Light Up Soon

17 Thoughts on Biotech Stocks to Kick Off 2017

Depomed Reports Dip in Earnings, Reduces Revenue Guidance

Humana, Pharma Stocks Sink as Healthcare is Worst Performing Sector Wednesday